Supira Medical has announced the appointment of Azeem Latib (Montefiore Health Systems, New York, USA) as medical director.
The company credits Latib with having played a key role in the development of its novel percutaneous ventricular assist device (pVAD) technology, previously serving as a clinical advisor and attending the initial first-in-human cases. Latib will retain his current position as the section head of Interventional Cardiology and director of Structural Heart Interventions at Montefiore Health Systems.
“I am very excited to join the Supira team and believe it has an excellent offering with one system designed to support cardiovascular haemodynamics for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS) patients,” stated Latib. “The unique pump is designed to achieve the required high continuous flow without the risk of bleeding often associated with these types of devices. This will advance clinical practice and enable more physicians to confidently perform these procedures.”
Latib’s professional expertise focuses on complex coronary interventions and structural heart disease, as well as a passion for new device innovation, Supira Medical said in a press release. He has authored over 700 peer-reviewed articles and serves on the editorial board for several publications including the Journal of American College of Cardiology (JACC), Cardiovascular Revascularization Medicine and EuroIntervention. Latib is a member of several professional organisations including the American College of Cardiology (ACC) and the European Society of Cardiology (ESC).
“Latib is an esteemed leader in the interventional space and his insights have been critical throughout our development process,” commented Nitin Salunke, president and CEO of Supira Medical. “We are thrilled to welcome him to Supira’s leadership team and look forward to his continued expertise as we build upon our successful first-in-human experience and accelerate our clinical activities.”
“We are grateful to have a physician of Dr Latib’s calibre join the team as it speaks to the clinical importance of this technology,” stated Amr Salahieh, founder of Shifamed and chairman of Supira Medical’s Board. “His guidance will be critical as the company expands its clinical experience and prepares for the development of its pivotal study to support premarket approval.”